Eli Lilly to Buy Dermira for $1.1 Billion
Eli Lilly agreed to buy biopharmaceutical company Dermira, Inc. for $18.75 a share, or approximately $1.1 billion in cash.
All articles by Heidi W. Moore
Secukinumab Provides Sustained Improvement in Nail Psoriasis
Researchers reported on the efficacy of secukinumab in patients with psoriatic arthritis and nail psoriasis and other elements of the disease, including radiographic progression.
Teledermatology – Access to Specialized Care Via a Different Model
Teledermatology offers near-immediate access to specialty medicine for underserved populations. Robert Stavert, MD, MBA, describes the successful physician-to-physician model his team employs at a safety net healthcare system.
Interleukin-23 Blocker Risankizumab Promising for Psoriasis
In this first report of a head-to-head trial comparing risankizumab and adalimumab, the former agent was found to demonstrate greater efficacy in patients with moderate to severe plaque psoriasis.
